![]() ![]() Deutsche Biotechnologietage 2023 Wiesbaden (German Biotech Days 2023).BIO 2023 Boston (BIO International Convention).Morgan 41st Annual Healthcare Conference 2023 San Francisco Jefferies Cell and Genetic Medicine Summit 2022 New York.World Molecular Imaging Congress 2022 (WMIC 2022) Miami Beach.SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™). Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Please contact us at to obtain the appropriate product information for your country of residence.Īll third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. SOPHiA Hereditary Cancer Solution, SOPHiA Myeloid Solution, SOPHiA Solid Tumor Solution are available as CE-IVD product for In Vitro Diagnostic Use in Europe, Turkey and Israel. We are excited to work with SOPHiA to provide this new combined offering to clinical researchers around the world.”įor more information, please visit SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. “Pairing our industry-leading, rapidly customizable enrichment efficiency with SOPHiA’s robust analytical platform provides customers an important solution to achieve clinically actionable data while saving on sequencing costs. Leproust, Ph.D., CEO and co-founder of Twist. “Genomics research is enabling a shift from broad-based “one-size-fits-all” approach to a personalized experience,” commented Emily M. “The combined solution will ultimately help experts precisely detect and characterize genomic mutations and use that information to improve outcomes.” “SOPHiA’s mission is to democratize access to Data-Driven Medicine all around the world.With the addition of SOPHiA’s technology to Twist’s advanced products, clinical researchers will benefit from end-to-end, highly-accurate and reliable genomic solutions,” commented Jurgi Camblong CEO and Co-founder of SOPHiA GENETICS. Genomic solutions that combine Twist NGS enrichment solutions along with the SOPHiA AI-powered Platform for advanced DNA analysis are designed to support the implementation of NGS application for somatic and germline testing. Target enrichment enables genomic sequencing efforts to be focused in specific regions of interest, which reduces cost and analysis time. Sequencing the whole genome is expensive and often does not provide the depth of information needed for individual genes and the role they play in complex diseases. Together, the technologies will allow a customer to go from sample to interpretation of the results quickly and efficiently. ![]() 26, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with SOPHiA GENETICS, leader in Data-Driven Medicine to bring access to the universal SOPHiA Platform for advanced genomic analysis to Twist’s customers, providing the analysis and interpretation of sequencing information. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |